Skip to Content

View Additional Section Content

Cardiovascular Clinical Research

The University of Missouri Health System has conducted clinical trials for more than 40 years. Many of these trials have resulted in approval of new drugs from the Food and Drug Administration. The broad experience of our research team combined with our wide range of clinical opportunities makes the health system an attractive site for conducting clinical research.

Volunteers help speed future improvements in medical care to those in need. The University of Missouri Health System has a broad base of clinical trial opportunities available to volunteers such as you. Talk with your physician about participating in these trials. 

To refer a patient to any cardiovascular medicine trial page the on-call pager number 573-499-8084.

Clinical Trials Currently Enrolling

CANTOS

  • Webel/Aggarwal/Kumar/Cyrus

Canakinumab vs. Placebo in the prevention of recurrent cardiovascular events in Post-MI patients with elevated hsCRP

RAID

  • Flaker/Weachter/Sullivan

Late Sodium Current Blockade in High-Risk ICD patients using Ranolazine vs. Placebo

GLAGOV

  • Webel/Aggarwal/A. Kumar/A. Chan

The Effects of AMG 145 vs. Placebo on Atherosclerotic disease burden as measured by IVUS in subjects undergoing coronary catheterization

FOURIER

  • Webel/Aggarwal/A. Kumar/A. Chan

Assessing the impact of additional LDL-C reduction on MACE when AMG 145 vs. Placebo is used in combination with statin therapy in patients with clinically evident CV disease

Registry Trials Currently Enrolling

ACTION

  • Aggarwal

Can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA Guidelines

Medtronic--PPP/AAF

  • Weachter/Flaker/Sullivan

Post-market surveillance to document product performance assessment of Medtronic device leads

Ongoing Clinical Trials - Not Enrolling

EXACT-HF

  • Flaker/Dohrmann

Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients using Allopurinol vs. Placebo

IMPROVE-IT

  • Aggarwal/Weachter/Flaker

Vytorin vs. Simvastatin in High Risk subjects presenting with ACS

PEGASUS--TIMI 54

  • Aggarwal/Kumar

Ticagrelor vs. Placebo to assess the prevention of thrombotic events in patients 1-3 years post MI

REVEAL TIMI--55

  • Aggarwal/Webel

Does inhibition of cholesteryl ester transfer protein (Anacetrapib vs. Placebo) prevent major vascular events in patients with vascular disease?

Pre-Determine

  • Flaker

Observational prospective study to identify genetic markers & biomarkers that predict the risk of arrhythmic death among CAD patients with preserved left ventricular ejection fraction (LVEF >35%)

TRANSLATE--ACS

  • Webel

Observational prospective study to assess treatment with ADP receptor inhibitors after hospitalization with an ACS event